Recursion Pharmaceuticals is exploding higher today following the announcement that the company has extended its data licensing agreement with Tempus AI through November 2029. This strategic deal locks in 42 million dollars in value and provides the company with significantly longer visibility regarding its platform revenue. While the broader biotechnology sector is seeing modest gains from peers like CRISPR Therapeutics, the primary driver for this move is the specific expansion of the Tempus AI partnership.